Climb Bio, Inc. (CLYM)
10.29
+1.42
(+16.01%)
USD |
NASDAQ |
Nov 06, 16:00
10.25
-0.04
(-0.39%)
After-Hours: 20:00
Climb Bio Research and Development Expense (Quarterly) : 10.85M for Sept. 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 10.85M |
| June 30, 2026 | 9.681M |
| March 31, 2026 | 9.335M |
| December 31, 2025 | 13.74M |
| September 30, 2025 | 9.073M |
| June 30, 2025 | 6.575M |
| March 31, 2025 | 17.33M |
| December 31, 2024 | 5.959M |
| September 30, 2024 | 3.518M |
| June 30, 2024 | 1.046M |
| March 31, 2024 | 1.091M |
| December 31, 2023 | 3.127M |
| September 30, 2023 | 2.876M |
| Date | Value |
|---|---|
| June 30, 2023 | 3.688M |
| March 31, 2023 | 5.72M |
| December 31, 2022 | 4.927M |
| September 30, 2022 | 4.258M |
| June 30, 2022 | 8.769M |
| March 31, 2022 | 8.26M |
| December 31, 2021 | 6.879M |
| September 30, 2021 | 5.989M |
| June 30, 2021 | 5.793M |
| March 31, 2021 | 4.661M |
| September 30, 2020 | 1.947M |
| June 30, 2020 | 1.36M |
| March 31, 2020 | 1.623M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Korsana Biosciences, Inc. | 42.14M |
| Cullinan Therapeutics, Inc. | 44.44M |
| Q32 Bio, Inc. | 5.149M |
| Arrowhead Pharmaceuticals, Inc. | 192.06M |
| Oncolytics Biotech, Inc. | 4.262M |